A clear look at the biology behind GLP-1 medications and why they work. These articles explain how the drugs curb appetite, regulate blood sugar, and influence metabolism, without the jargon.
Science & How It Works
Combination obesity drugs that target several hormone pathways at once are moving from trials toward approval. Retatrutide posted 28.3% average weight loss in Phase 3, and CagriSema is under FDA review. Here is what that means for patients on GLP-1 therapy now.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, but emerging research raises questions about whether they may also reduce physical activity levels. Understanding this potential tradeoff helps you make smarter choices about exercise while on treatment. Here is what the science suggests and what you can do about it.
New research suggests GLP-1 receptor agonists may reduce the risk of tuberculosis in people with type 2 diabetes, adding to a growing list of health benefits beyond blood sugar and weight control. Here is what the findings mean for patients currently taking or considering semaglutide or tirzepatide, and what questions to bring to your doctor.
Research is building around an unexpected pattern: people taking GLP-1 medications for weight loss are reporting reduced cravings for alcohol, nicotine, and other addictive substances. Here is what the current science shows, what it means for patients, and the questions worth asking your doctor.
New research suggests that weekly GLP-1 receptor agonists may outperform insulin for managing one type of diabetes. This breakdown explains what the findings mean for patients, what questions to ask your doctor, and how GLP-1 medications compare in cost and convenience.
GLP-1 medications like semaglutide and tirzepatide have changed obesity treatment, but the next generation goes even further. New combination hormone therapies are showing stronger weight loss results with potentially fewer side effects. Here is what patients and those considering treatment need to know.
Emerging research suggests GLP-1 medications like semaglutide and tirzepatide may do more than control blood sugar and support weight loss. Studies are finding these drugs may also reduce alcohol cravings and consumption. Here's what the science shows and what it means for you.
GLP-1 medications like Ozempic are quietly reshaping how people eat at work, and colleagues are noticing. From skipped team lunches to awkward food-push moments, here's what patients are experiencing and how to handle it with confidence.